Aracatuba

Researchers are evaluating the safety and effectiveness of BGB-16673 compared to pirtobrutinib in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with a covalent Bruton tyrosine kinase inhibitor cBTKi. The study is a phase 3, open-label, randomized trial sponsored by BeOne Medicines, aiming to assess treatment options for these patients. Participants are randomly assigned to receive either BGB-16673 or pirtobrutinib, both taken orally. This parallel assignment design compares these two drugs directly. The treatments continue with monitoring up to approximately three years to observe progression-free survival and other outcomes. The study began in September 2025 and is expected to complete in April 2028. During the trial, participants will undergo regular assessments including imaging scans to measure disease status, quality of life questionnaires, and monitoring for adverse events. Outcomes such as overall survival, response rates, duration of response, and time to next treatment are tracked. Safety and quality of life will be evaluated throughout the study period, which may last up to about three years for each participant.

Researchers are conducting the BRAVO study, a multicenter observational research project focused on adults aged 18 and over living with HIVAIDS across Brazil. The study aims to gather detailed information about chronic non-communicable diseases NCDs, mental health, and quality of life in this population to help develop better health policies. It includes participants from various regions in Brazil and emphasizes the importance of understanding cardiometabolic health, mental health, and other risk factors among people living with HIVAIDS. The study collects a wide range of data including sociodemographic details, risk factors for main NCDs, physical examination results, and biological samples for biochemical and metabolic testing. It uses validated tools and some project-developed questionnaires to assess conditions such as depression, anxiety, substance use, and quality of life through the WHOQOL-BREF survey. Data are managed using REDCap software and cover clinical lab tests, physical measures, respiratory function, renal, hepatic, and bone health, as well as sexually transmitted infections and cancer risk assessments. Participants will provide informed consent and undergo a cross-sectional baseline assessment during 2025 and 2026. Researchers will measure the prevalence of chronic diseases, mental disorders, metabolic and behavioral risk factors, antiretroviral therapy adherence, and quality of life at baseline and one year later. The study plans subgroup analyses for specific populations and ensures confidentiality and ethical compliance. Participation involves data collection through questionnaires, exams, and sample collection, with a target of 743 participants to ensure reliable results.

Researchers are evaluating the effectiveness of DYNAVISC in adults diagnosed with persistent or recurrent carpal tunnel syndrome after previous surgery. This prospective, multicenter, randomized, and evaluator-blinded clinical trial compares two methods for protecting the median nerve during revision surgery standard surgery followed by DYNAVISC application and standard surgery followed by coverage with a hypothenar fat pad flap. Participants will receive revision surgery, after which half will have DYNAVISC 1 ml applied around the median nerve by the surgeon, while the other half will have the nerve covered with a hypothenar fat pad flap. Following surgery, participants will begin gentle wrist and finger movements immediately and gradually increase activity to more strenuous movements starting six weeks after surgery. Follow-up visits for hand evaluations are scheduled at 1 week, 4 weeks, and 12 weeks post-surgery. Throughout the study, participants will report pain levels using a visual analog scale VAS, hand function using the Quick DASH Score, neuropathic pain using the DN4 assessment, and undergo nerve conduction tests with electroneuromyography. Grip strength will be measured with a dynamometer. All assessments will occur at baseline and follow-up visits with evaluators unaware of the treatment group. The main outcome is pain reduction at 12 weeks post-surgery, with additional measures of hand function, nerve recovery, and strength also monitored.